2026 – Talk Bio

J&J Targets $100 Billion in 2026 Sales Despite Stelara Patent Cliff

4 days ago talkbio0Tagged 2026, Darzalex, J&J, Johnson & Johnson, medtech, Neoplasms, Patent Cliff, Sales - occupational activity, Shockwave Medical, Stelara

Johnson & Johnson; J&J; 2026 sales; $100 billion; Stelara; patent cliff; DARZALEX; oncology; MedTech; Shockwave Medical

VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026

3 weeks ago talkbio0Tagged 2026, AI-driven, Attitude, Funding, Investments, IPO, M&A activity, MassBio, rates, venture capital, Vital capacity, Window (physical object)

venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment

VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026

3 weeks ago talkbio0Tagged 2026, AI-driven, Attitude, Funding, Investments, IPO, M&A activity, MassBio, rates, venture capital, Vital capacity, Window (physical object)

venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment

VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026

3 weeks ago talkbio0Tagged 2026, AI-driven, Attitude, Funding, Investments, IPO, M&A activity, MassBio, rates, venture capital, Vital capacity, Window (physical object)

venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment

VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026

3 weeks ago talkbio0Tagged 2026, AI-driven, Attitude, Funding, Investments, IPO, M&A activity, MassBio, rates, venture capital, Vital capacity, Window (physical object)

venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment

Spotlight On: Five key oncology stories to watch in 2026

3 weeks ago talkbio0Tagged 2026, Antibody-Drug Conjugates, cancer research trends, CAR-T, Cell Therapy, Liquid Biopsy, Lymphocytes, Tumor-Infiltrating, mRNA cancer, Neoplasms, oncology decisions, precision oncology, Radiopharmaceuticals, T-Cell Receptor, United States Food and Drug Administration, Vaccines

oncology 2026; cancer research trends; FDA oncology decisions 2026; antibody-drug conjugates; radiopharmaceuticals; liquid biopsy; mRNA cancer vaccines; AI in oncology; cell therapies CAR-T TIL TCR; precision oncology

Spotlight On: 2026 Predictions – Where’s AI in Healthcare Heading?

2 months ago talkbio0Tagged 2026, Efficiency, Health care facility, healthcare operational, medical documentation AI, predictive, wearable technology healthcare

AI in healthcare 2026; medical documentation AI; wearable technology healthcare; predictive analytics EHR; AI patient communication; healthcare operational efficiency; AI healthcare trends

From JP Morgan to the Next Wave: What’s Driving Biotech in 2026

3 months ago talkbio0Tagged 2026, Artificial Intelligence, Drug Discovery, Hematology (discipline), Investments, J.P. Morgan Healthcare Conference, M&A activity, Neoplasms, Neuropsychology, regulatory science, trends qualifier

J.P. Morgan Healthcare Conference; biotech trends 2026; M&A activity; oncology; neuropsychology; hematology; artificial intelligence; drug discovery; investment; regulatory science

Novartis to Acquire RNA Drugmaker Avidity Biosciences in $12 Billion Deal

3 months ago talkbio0Tagged 2026, Acquisition, AOC, Avidity Biosciences, Closed, Muscular Dystrophy, Duchenne, Muscular Dystrophy, Facioscapulohumeral, MYOTONIC DYSTROPHY 1, Neuromuscular Diseases, Novartis, Platform, RNA therapeutics, SpinCo ', xRNA

Novartis; Avidity Biosciences; acquisition; RNA therapeutics; neuromuscular diseases; Duchenne muscular dystrophy; myotonic dystrophy type 1; facioscapulohumeral muscular dystrophy; AOC platform; SpinCo; biotech; xRNA strategy; 2026 closing